Ever Fortune.AI medical software nets one more approval for the US market

Source in Chinese: Commercial Times

Ever Fortune.AI announced on 26 September that its “EFAI RT Suite CT HCAP-Segmentation System” has been greenlighted by FDA. Currently, Ever Fortune has obtained 11 approvals from Taiwan’s FDA and 7 from the US.

According to Ever Fortune.AI, this breakthrough medical software is based on a closed-loop artificial intelligence algorithm module that automatically delineates 17 types of head-and-neck organs-at-risk on CT images, and transmits the result to the Treatment Planning System (TPS) for healthcare professionals to view, edit, and make manual corrections as necessary.

In addition, the product will not have any impact on the computed tomography (CT) photography process and will not modify the original CT images. The launch of this medical software will further accelerate the workflow of radiotherapy and shorten the time of treatment plans, thus providing patients with a more convenient and efficient medical experience.

Ever Fortune.AI is the first medical AI company in Taiwan to go public, specialising in the areas of neurology, cardiology, and oncology, which can be considered the ‘blue ocean’ of medical AI due to their high entry barriers, high product values, and large market demands.

The "EFAI RT Suite CT HCAP-Segmentation System" approved this time is part of the company’s roadmap developed for oncology, while it has products that have been greenlighted to serve cardiovascular and brain neurology. Ever Fortune.AI’s customers include more than 40 medical institutions and corporations in the United States, France, Singapore, Hong Kong, China and Taiwan, and the addition of the new product will facilitate the retention of existing customers and the development of new customers.